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Abstract: Glaucoma is a chronic progressive optic neuropathy characterized by progressive loss 
of retinal ganglion cells, which manifests clinically with loss of optic disc neuroretinal rim tissue, 
defects in the retinal nerve ﬁ  ber layer, and deﬁ  cits on functional visual ﬁ  eld testing. The goal of 
glaucoma treatment is to reduce the intraocular pressure to a level that prevents or minimizes 
the progressive loss of vision. The current standard of management for the newly diagnosed 
primary open angle glaucoma (PAOG) patient is to start topical medication. Available topical 
medications include: beta-adrenergic antagonists, alpha-adrenergic agonists, carbonic anhydraze 
inhibitors, prostaglandin analogues and miotics. In some patients, IOP is not adequately controlled 
by monotherapy. In those refractory patients, where more efﬁ  cacy is required, shifting to another 
medication or adding a second medication is indicated. The complimentary action between two 
drugs serves as the basis for combination medications. One avenue of delivering a second medica-
tion is through a ﬁ  xed combination medication that has the advantage of providing two medicines 
within one drop. Bimatoprost/timolol represents a new ﬁ  xed combination which is clinically 
and statistically more effective than either of its active constituents for patients with refractory 
glaucoma. As regard the safety of the combination, there were no signs or symptoms of intoler-
ance and the incidence of conjunctival hyperemia was clinically and statistically signiﬁ  cantly 
less than each of the two components separately. Bimatoprost/timolol ﬁ  xed combination offers 
cost and time savings, which may enhance compliance; also reducing the amount of preservative 
applied to the eye, will improve tolerability and may also favorably improve eventual surgical 
outcomes in patients who might require ﬁ  ltering procedures.
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Glaucoma is a chronic progressive optic neuropathy characterised by progressive loss 
of retinal ganglion cells, which manifests clinically with loss of optic disc neuroretinal 
rim tissue, defects in the retinal nerve ﬁ  ber layer, and deﬁ  cits on functional visual ﬁ  eld 
testing (Danesh-Meyer et al 2006).
In the United States, glaucoma is the second leading cause of blindness in the gen-
eral population, and the leading cause of blindness in black patients. The pathogenesis 
of glaucomatous optic neuropathy remains incompletely understood. While elevated 
intraocular pressure (IOP) is a clear risk factor, vascular insufﬁ  ciency and abnormal 
autoregulation of the optic nerve circulation have been hypothesized to play a sig-
niﬁ  cant role in the development and progression of glaucoma (Hayreh 1969; Ernest 
1975; Sossi and Anderson 1983). Primary open-angle glaucoma (POAG) is the most 
common form of glaucoma in the United States. The number of people with POAG 
worldwide in the year 2000 has been estimated at nearly 66.8 million, with 6.7 million 
having bilateral blindness (Quigley 1996).
The goal of glaucoma treatment is to reduce the intraocular pressure to a level 
that prevents or minimizes the progressive loss of vision (Jay and Murray 1988; GLT 
1990; Spaeth and Baez 1992; AGIS 1998; King and Migdal 2000).Three modalities 
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of treatment are available including: medical therapy, laser 
surgery and conventional incisional surgery. Despite contin-
ued advances in laser and incisional surgery, medical therapy 
continues to be the primary means by which IOP is controlled 
(Schwartz and Bundez 2004).
The current standard of management for the newly diag-
nosed POAG patient is to start topical medication (Anderson 
1989). Monotherapy with a single medication is usually tried 
ﬁ  rst; however, many patients need more than one medication 
to lower IOP sufﬁ  ciently to prevent progression. Available 
topical medications include: beta-adrenergic antagonists, 
alpha-adrenergic agonists, carbonic anhydrase inhibitors, 
prostaglandin analogues, and miotics.
Beta-blockers are highly effective in treating glaucoma 
(Zimmerman and Kaufman 1977a; Boger et al 1978; Radius 
et al 1978; Ritch et al 1978; Obstbaum et al 1978; Lin et al 
1979) and were initially considered ﬁ  rst line treatment. 
They reduce IOP by inhibiting aqueous humour production 
(Coakes and Brubaker 1978). Although they are usually well 
tolerated and are commonly used as monotherapy, they do 
have both local and systemic side effects. Local side effects 
include hyperemia of the conjunctiva, burning sensation, 
superﬁ  cial punctuate keratitis and reduced tear ﬂ  ow (Van 
Buskirk 1980). Systemic side effects, which are of more 
concern, may be induced by blocking the β1-adrenoceptors 
of the heart resulting in bradycardia, arrhythmia, congestive 
heart failure and syncope by Adam-stokes syndrom (Nelson 
et al 1986; McMahon et al 1979). Furthermore, blocking the 
β2-adrenoceptors of the bronchioles may cause bronchospasm 
in patients with chronic obstructive pulmonary disease or 
asthma (Sadiq et al 1998).
Topical carbonic anhydrase inhibitors (CAIs) lower IOP by 
decreasing aqueous production (Maus et al 1997). The most 
frequent side effects of CAIs include burning sensation, ocular 
discomfort, superﬁ  cial punctuate keratitis and allergic conjunc-
tivitis (Strahlman et al 1995). CAIs also may impair the corneal 
endothelial pump function, thus causing corneal decompansa-
tion in predisposed patients (Konowal et al 1999).
Prostaglandin analogues are now considered the ﬁ  rst 
line of treatment in POAG (Camras 1999). The reduction 
of IOP by prostaglandin analogues is based on an increase 
in trabecular and uveoscleral outﬂ  ow (Mishima et al 1977). 
While no systemic side effects have been reported with 
prostaglandins, local side effects include conjunctival 
hyperemia, stinging, burning sensation, punctuate keratitis, 
increased iris pigmentation, as well as cystoid macular edema 
in pseudophakic patients (Camras 1996; Selen et al 1997; 
Ayyala et al 1998).
In some patients, IOP is not adequately controlled by 
monotherapy. In those refractory patients, where more efﬁ  -
cacy is required, shifting to another medication or adding a 
second medication is indicated. The complimentary action 
between two drugs often serves as the basis for combination 
medications.
β-blockers can be combined well with miotics, topical 
CAIs, brominidine, and prostaglandin analogues. The 
efﬁ  cacy of combining β-blockers with pilocarpine has 
been shown in various studies (Keates 1979; Kass 1983). 
The ocular side effects of pilocarpine include inducing 
myopia, headache, blurred vision, conjunctival hyperaemia, 
lens opacities and retinal detachments in predisposed 
patients (Levene 1975; Pape and Forbes 1978), limiting 
its usefulness.
One avenue of delivering a second medication is through 
a ﬁ  xed combination medication that has the advantage of 
providing two medicines within one drop. Such a product 
potentially reduces confusion from multiple bottles, aids 
compliance, lowers patient costs, and helps eliminate 
potential washout effects (Fechtner and Realini 2004). In 
addition; safety might be theoretically increased by using 
a ﬁ  xed combination product, which limits the exposure to 
benzalkonium chloride, a preservative in most eye drops that 
has demonstrated signiﬁ  cant corneal epithelial toxicity that 
is dose dependent.
Topical CAIs are complimentary in ocular hypotensive 
efﬁ  cacy when combined with β-blockers (Kass et al 1982). 
Dorzolamide/timolol ﬁ  xed combination (DTFC) was found 
to be as effective as the concomitant administration of its 
components in reducing IOP and has also simpliﬁ  ed the 
therapy for patients needing these two medications (Boyle 
et al 1991). DTFC twice daily provided better IOP control 
than prostaglandin analogues once daily (Parmaksiz et al 
2006). For patients with pseudoexofoliation glaucoma 
(PXG), diurnal ﬂ  uctuation of IOP is higher than in patients 
with POAG (Konstas et al 1997). Because damage to the 
optic nerve might be associated with ﬂ  uctuations in IOP, a 
drug that consistently controls IOP throughout the diurnal 
curve may be an important choice for the medical treatment 
of refractory glaucomas such as PXG (Asrani et al 2000). 
In addition dorzolamide has been reported to increase blood 
ﬂ  ow in animal models and in healthy and glaucomatous 
patients (Harris et al 1999; Josefsson et al 2004). Several 
other studies have suggested that dorzolamide enhances 
ocular blood ﬂ  ow, including studies investigating the choroid 
(Harris et al 2003) and the retrobulbar vessels (Martinez 
et al 1999).Clinical Ophthalmology 2008:2(1) 17
Timolol/bimatoprost for refractory glaucoma
Fixed combination brimonidine/timolol provides a 
combination of a β-blocker that reduces IOP by inhibit-
ing aqueous production (Coakes and Brubaker 1978) and 
brimonidine, an alpha-adrenergic receptor agonist that has 
a dual mechanism of action:increasing uveoscleral outﬂ  ow 
and reducing aqueous production.
Another potentially useful ﬁ  xed combination is β-blocker 
to prostaglandin analogue, which has proven to be effec-
tive in controlling IOP in refractory patients (Villumsen 
and Alm 1990). The mechanism of action of prostaglandin 
analogues is complimentary to the IOP lowering mecha-
nism of β-blockers. Available lipid/timolol combinations 
(latanoprost/timolol and travoprost/timolol), have a similar 
complementary mechanism of action (Toris et al 1995).
The latanoprost/timolol ﬁ  xed combination dosed in the 
evening demonstrated a lower absolute IOP level at each time 
point and for 24- hours curve. Also, the maximum, minimum, 
and range of pressure were lower with the latanoprost/timolol 
ﬁ  xed combination than with either drug alone (Anastasios 
et al 2006). Adverse events included conjunctival hyperemia, 
ocular stinging and itching were observed frequently with the 
latanoprost/timolol ﬁ  xed combination (Shen et al 2004).
Another new ﬁ  xed combination is bimatoprost 0.03% 
or 0.3 mg/mL + timolol 0.5% or 5 mg/mL. Bimatoprost is 
a synthetic prostamide, structurally related to prostaglandin 
F (PGF) that does not act through any known prostaglandin 
receptors. It reduces intraocular pressure by increasing aque-
ous humour outﬂ  ow through the trabecular meshwork and 
enhancing uveoscleral outﬂ  ow.
Timolol maleate is a non-selective adreno-receptor 
antagonist that does not have signiﬁ  cant intrinsic sympathomi-
metic activity or membrane stabilizing activies. Blocking the 
beta-adrenoreceptors results in reduction of the intracellular 
second messenger, cAMP, believed to be involved in aqueous 
humour dynamics. Timolol does not have any effect on the 
outﬂ  ow mechanism and exerts its effect on IOP by reducing 
aqueous humour production (Yablonski et al 1978). Timolol 
0.5% was selected as the preferred dose in the bimatoprost/
timolol ﬁ  xed combination product, as the 0.25% concentration 
is considered to be suboptimal in the poorly controlled patient. 
In addition, the use of timolol 0.5% once-daily has been shown 
to provide a beneﬁ  cial effect on IOP over a 24-hour period, 
an effect that was less pronounced with 0.25% concentration 
(Zimmerman and Kaufman 1977b).
Studies have shown that bimatoprost/timolol fixed 
combination was rapidly absorbed and distributed into 
ocular tissues in close contact with the administration 
site. This concentration was highest in the iris and ciliary 
body which are the sites of pharmacological action. The 
pharmacokinetic parameters of bimatoprost/timolol ﬁ  xed 
combination were similar with either single or combination 
treatment (EPAR 2007).
Systemic absorption of topical administration is well 
known. As expected, bimatoprost and timolol were detected 
systemically following ocular instillation. Systemic concen-
trations of bimatoprost and timolol are slightly lower when 
administered in combination versus single administration. 
Differences in metabolism of the two drugs suggest that they 
will not affect or alter one another (EPAR 2007).
For a ﬁ  xed combination medication to be truly clini-
cally advantageous, it must increase efﬁ  cacy beyond each 
of its individual components given as monotherapy without 
decreasing safety (De Saint et al 2000). Brandt et al 2007, 
reported that the combination was effective, lowering mean 
IOP from baseline by up to 9.6 mmHg, and clinically and 
statistically superior to each constituent as judged by the 
overall criterion of 20% reduction in mean diurnal IOP, 
and maintaing the mean diurnal IOP below 18 mmHg at all 
visits. Also the reduction in IOP with the combination was 
numerically greater than for either active component and 
statically signiﬁ  cant at most of the time points and visits.
As regards the safety of the combination, there were 
no signs or symptoms of intolerance and the incidence of 
conjunctival hyperemia was clinically and statistically less 
signiﬁ  cant than each of the two components separately. 
The reason for the decreased incidence of conjunctival 
hyperemia is not clear. One possible explanation is that 
the α1-adrenoceptor agonistic effects of endogenous cat-
echolamines, now unopposed by β2-adrenoceptor agonistic 
effects due to blockade by the timolol. Another explanation 
is that the antagonism of β2-adrenoceptors by timolol could 
diminish the production of nitric oxide (Arai et al 2003), a 
mediator of bimatoprost-associated hyperemia (Chen et al 
2005). Irrespective of the mechanism, the conjunctival 
hyperemia associated with bimatoprost is non-inﬂ  ammatory 
(Leal et al 2004).
Actually the fixed combination of bimatoprost and 
timolol was clinically and statistically signiﬁ  cantly more 
effective than either of its active constituents for patients 
with refractory glaucoma, for those patients requiring two 
or more ocular hypotensive medications, this single-bottle, 
fixed combination represents a convenient, therapeutic 
advantage over separate bottles. Also it represents a reduc-
tion in the number of drops per day that is required for the 
patient to instill. An established washout effect resulting from 
rapid sequence instillation of two medications requires that Clinical Ophthalmology 2008:2(1) 18
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patients wait approximately 5 minutes between eye drops 
(Chrai et al 1947). Bimatoprost/timolol ﬁ  xed combination 
offers a reduced time commitment for drop instillation and 
the potential for greater efﬁ  cacy by eliminating the washout 
effect. Bimatoprost/timolol ﬁ  xed combination offers cost and 
time savings, which may enhance compliance; also reducing 
the amount of preservative applied to the eye, will improve 
tolerability and may also favorably improve eventual surgical 
outcomes in patients who might require ﬁ  ltering procedures 
(Lavin et al 1990; Broadway et al 1994).
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